Congress cuts Medicaid for gender care, hitting low-income families hardest

What it does

This bill prohibits federal Medicaid funding for gender transition procedures and puberty-blocking medications for minors under 18, with narrow exceptions for treating genetic disorders of sex development and correcting complications from prior procedures. It does not ban these procedures outright—only federal Medicaid payment for them—leaving private insurance, out-of-pocket payment, and state-funded alternatives available.

Why we flagged it

The bill's operative mechanism is a federal funding exclusion—it amends Medicaid statute to bar reimbursement for specified procedures and medications. The title frames this as harm prevention, but the functional effect is a funding restriction on a category of medical care, not a ban on the care itself.

What the text implies

• States that currently fund gender transition care for minors through Medicaid will face pressure to defund or restrict those services, as federal matching funds are withdrawn. This creates a de facto national policy even though states retain nominal authority.
• The definition of 'specified gender transition procedures' is extremely broad and includes puberty-blocking medications at 'supraphysiologic' doses—a term that may capture standard clinical dosing, creating ambiguity about what is actually prohibited.
• The exception for 'medically verifiable genetic disorders of sex development' is narrow and requires physician certification; minors with gender dysphoria (a psychiatric diagnosis, not a genetic disorder) fall outside this exception entirely.
• Low-income families will face disproportionate barriers to accessing these procedures, as private insurance and out-of-pocket payment remain available to higher-income families—creating a de facto wealth-based access divide.
• Pharmaceutical companies supplying puberty blockers and hormone therapies will see reduced Medicaid volume, but private and state-funded demand may offset losses; the net market impact depends on state-level responses.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill restricts access to a category of medical care for a vulnerable population (minors) by removing federal funding, which will increase out-of-pocket costs and reduce availability for low-income families relying on Medicaid. However, the bill reflects a genuine policy disagreement about appropriate medical care for minors, and the restriction applies only to federal dollars, not to private or state funding—a meaningful but not absolute barrier.

Named in the bill

U.S. Department of Health and Human Services, State Medicaid agencies, Pharmaceutical manufacturers (Pfizer, Bristol Myers Squibb, Janssen, others), Healthcare providers specializing in gender medicine, Medicaid-enrolled minors and families

Where it stands

6 cosponsors: 6 Republicans.

• Jan 16, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jan 16, 2025 — Referred to House Committee on Energy and Commerce and Senate Committee on Finance · Congress.gov: “Referred to the House Committee on Energy and Commerce”
• Dec 18, 2025 — Passed the House · Congress.gov: “On passage Passed by the Yeas and Nays: 215 - 201 (Roll no. 362). (text: CR H6057)”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 6 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,173,908 in lobbying spend. A filing names 106 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

Dan Crenshaw, the sponsor, reported $606,011 in PAC receipts in the 2026 cycle.

• American Federation of State County and Municipal Employees — $690,000 on 1 filing
• Human Rights Campaign — $439,908 on 2 filings
• National Association of Pediatric Nurse Practitioners — $24,000 on 1 filing
• National Council of Jewish Women — $20,000 on 2 filings

Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.